FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969705364> ?p ?o ?g. }

• W2969705364 endingPage "2083" @default.
• W2969705364 startingPage "2071" @default.
• W2969705364 abstract "IntroductionProgrammed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of good response and long survival with anti–PD-1 therapy have yet to be identified; therefore, predictive biomarkers are needed to select patients with benefits.MethodsWe conducted a prospective study to explore whether serum antibody against NY-ESO-1 and/or XAGE1 cancer-testis antigens predicted primarily good clinical response and secondarily long survival with anti–PD-1 therapy for NSCLC. The serum antibody was detected by enzyme-linked immunosorbent assay, and tumor immune microenvironment and mutation burden were analyzed by immunohistochemistry and next-generation sequencing.ResultsIn the discovery cohort (n = 13), six antibody-positive NSCLC cases responded to anti–PD-1 therapy (two complete and four partial responses), whereas seven antibody-negative NSCLC cases did not. Antibody positivity was associated with good response and survival, regardless of tumor programmed death ligand 1 (PD-L1) expression, mutation burden, and CD8+ T-cell infiltration. In the validation cohort (n = 75), 17 antibody-positive NSCLC cases responded well to anti–PD-1 therapy as compared with 58 negative NSCLC cases (objective response rate 65% versus 19%, p = 0.0006) and showed significantly prolonged progression-free survival and overall survival. Antibody titers highly correlated with tumor reduction rates. In the multivariate analysis, response biomarkers were tumor programmed death ligand 1 expression and antibody positivity, and only antibody positivity was a significantly better predictive biomarker of progression-free survival (hazard ratio = 0.4, p = 0.01) and overall survival (hazard ratio = 0.2, p = 0.004).ConclusionsOur results suggest that NY-ESO-1 and/or XAGE1 serum antibodies are useful biomarkers for predicting clinical benefits in anti–PD-1 therapy for NSCLC and probably for other cancers." @default.
• W2969705364 created "2019-08-29" @default.
• W2969705364 creator A5009325297 @default.
• W2969705364 creator A5009932798 @default.
• W2969705364 creator A5013524621 @default.
• W2969705364 creator A5015230576 @default.
• W2969705364 creator A5016973358 @default.
• W2969705364 creator A5019476442 @default.
• W2969705364 creator A5024077345 @default.
• W2969705364 creator A5031939366 @default.
• W2969705364 creator A5037231478 @default.
• W2969705364 creator A5044883471 @default.
• W2969705364 creator A5052317767 @default.
• W2969705364 creator A5054033361 @default.
• W2969705364 creator A5069087687 @default.
• W2969705364 creator A5073365620 @default.
• W2969705364 creator A5075963647 @default.
• W2969705364 creator A5076225179 @default.
• W2969705364 creator A5077762603 @default.
• W2969705364 creator A5086141560 @default.
• W2969705364 creator A5089569598 @default.
• W2969705364 date "2019-12-01" @default.
• W2969705364 modified "2023-10-16" @default.
• W2969705364 title "Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC" @default.
• W2969705364 cites W1813077322 @default.
• W2969705364 cites W1877911682 @default.
• W2969705364 cites W1985594917 @default.
• W2969705364 cites W1986592841 @default.
• W2969705364 cites W1999042146 @default.
• W2969705364 cites W2019607817 @default.
• W2969705364 cites W2044433401 @default.
• W2969705364 cites W2049553585 @default.
• W2969705364 cites W2052407622 @default.
• W2969705364 cites W2079908599 @default.
• W2969705364 cites W2083667687 @default.
• W2969705364 cites W2085243878 @default.
• W2969705364 cites W2096910745 @default.
• W2969705364 cites W2099900951 @default.
• W2969705364 cites W2103876938 @default.
• W2969705364 cites W2104750134 @default.
• W2969705364 cites W2123879591 @default.
• W2969705364 cites W2131638796 @default.
• W2969705364 cites W2134121541 @default.
• W2969705364 cites W2145952980 @default.
• W2969705364 cites W2148876339 @default.
• W2969705364 cites W2157854273 @default.
• W2969705364 cites W2172131454 @default.
• W2969705364 cites W2232693424 @default.
• W2969705364 cites W2295190058 @default.
• W2969705364 cites W2340636398 @default.
• W2969705364 cites W2538232731 @default.
• W2969705364 cites W2540929992 @default.
• W2969705364 cites W2573782202 @default.
• W2969705364 cites W2588146309 @default.
• W2969705364 cites W2609289346 @default.
• W2969705364 cites W2619997833 @default.
• W2969705364 cites W2725398806 @default.
• W2969705364 cites W2753207486 @default.
• W2969705364 cites W2806388842 @default.
• W2969705364 cites W2895634939 @default.
• W2969705364 cites W2949273159 @default.
• W2969705364 cites W4242460399 @default.
• W2969705364 doi "https://doi.org/10.1016/j.jtho.2019.08.008" @default.
• W2969705364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31449889" @default.
• W2969705364 hasPublicationYear "2019" @default.
• W2969705364 type Work @default.
• W2969705364 sameAs 2969705364 @default.
• W2969705364 citedByCount "28" @default.
• W2969705364 countsByYear W29697053642020 @default.
• W2969705364 countsByYear W29697053642021 @default.
• W2969705364 countsByYear W29697053642022 @default.
• W2969705364 countsByYear W29697053642023 @default.
• W2969705364 crossrefType "journal-article" @default.
• W2969705364 hasAuthorship W2969705364A5009325297 @default.
• W2969705364 hasAuthorship W2969705364A5009932798 @default.
• W2969705364 hasAuthorship W2969705364A5013524621 @default.
• W2969705364 hasAuthorship W2969705364A5015230576 @default.
• W2969705364 hasAuthorship W2969705364A5016973358 @default.
• W2969705364 hasAuthorship W2969705364A5019476442 @default.
• W2969705364 hasAuthorship W2969705364A5024077345 @default.
• W2969705364 hasAuthorship W2969705364A5031939366 @default.
• W2969705364 hasAuthorship W2969705364A5037231478 @default.
• W2969705364 hasAuthorship W2969705364A5044883471 @default.
• W2969705364 hasAuthorship W2969705364A5052317767 @default.
• W2969705364 hasAuthorship W2969705364A5054033361 @default.
• W2969705364 hasAuthorship W2969705364A5069087687 @default.
• W2969705364 hasAuthorship W2969705364A5073365620 @default.
• W2969705364 hasAuthorship W2969705364A5075963647 @default.
• W2969705364 hasAuthorship W2969705364A5076225179 @default.
• W2969705364 hasAuthorship W2969705364A5077762603 @default.
• W2969705364 hasAuthorship W2969705364A5086141560 @default.
• W2969705364 hasAuthorship W2969705364A5089569598 @default.
• W2969705364 hasBestOaLocation W29697053641 @default.
• W2969705364 hasConcept C10515644 @default.
• W2969705364 hasConcept C121608353 @default.
• W2969705364 hasConcept C126322002 @default.
• W2969705364 hasConcept C143998085 @default.
• W2969705364 hasConcept C147483822 @default.

• next